Outpatient Versus Inpatient Administration of Ciltacabtagene Autoleucel in Multiple Myeloma: A Systematic Review of Clinical, Economic, and Humanistic Outcomes
Open Access
Abstract
Background/Objectives: Ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma is typically administered inpatient (IP) to monitor for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Because cilta-cel toxicities are typically delayed, outpatient (OP) administration (infusion and early monitoring) is being explored. We synthesized available evidence on OP and IP administration. Methods: MEDLINE, Embase, and Cochrane Library were searched from inception to 5 August 2025, supplemented by conference and gray literature searches. Eligible studies of adults with multiple myeloma receiving cilta-cel reported efficacy, safety, resource use, costs, and/or quality-of-life outcomes; findings were synthesized descriptively due to heterogeneity. Results: Seventy-four records (56 studies) were included; 90 patients received OP cilta-cel. OP clinical evidence (primarily three real-world studies) showed high response rates (ORR: 95%; median follow-up 4.6 months) and reported 1-year PFS and OS of 86% and 96%. In IP studies, median ORR was 91%, with median 1-year PFS 76% and median 1-year OS 85%. Any-grade CRS and ICANS occurred in 79–84% and 17–22% of OP patients (largely low grade); IP cohorts reported a median ICANS incidence of 17% (range 5–23%). Most OP patients were later hospitalized (86–93%), but stays were shorter (median 4–6.5 days) than in an IP cohort (median 19 days). Comparisons were unadjusted and may reflect selection differences. One modeling-based economic analysis estimated savings of ~$19,000 per OP-treated patient. Conclusions: OP cilta-cel appears feasible for selected patients and may reduce costs without compromising outcomes. Findings are descriptive and hypothesis-generating and prospective multicenter studies are needed to define long-term safety, durability, quality of life, and cost-effectiveness.Keywords
Funding Information
- Janssen Scientific Affairs
- Legend Biotech USA Inc
This publication has 83 references indexed in Scilit:
- Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter studyHemaSphere, 2025
- Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy NetworkTransplantation and Cellular Therapy, 2024
- Safety and Feasibility of Outpatient Administration of Ciltacabtagene Autoleucel (Cilta-cel)Transplantation and Cellular Therapy, 2024
- Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 TrialTransplantation and Cellular Therapy, 2024
- Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2023
- Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple MyelomaTransplantation and Cellular Therapy, 2023
- Patient Perceptions of CAR-T Therapy in the USA: Findings from In-Depth InterviewsOncology and Therapy, 2023
- Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple MyelomaOncology and Therapy, 2023
- Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment optionsBlood Reviews, 2021
- Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient AdministrationTransplantation and Cellular Therapy, 2021